Anti-Human GP IIb/IIIa (Abciximab Biosimilar)
英诺赛图(InnoCyto)的 Anti-Human GP IIb/IIIa (Abciximab Biosimilar)(克隆 Abciximab) 为人源 IgG1 Fab 抗体,靶向 CD41/CD61,适用于流式细胞术。提供 1 mg、5 mg、20 mg 规格,目录价 ¥1,695 起,仅供科研使用(RUO)。
01产品图片

02产品简介
英诺赛图(InnoCyto)的 Anti-Human GP IIb/IIIa (Abciximab Biosimilar)(克隆 Abciximab) 为人源 IgG1 Fab 抗体,靶向 CD41/CD61,适用于流式细胞术。提供 1 mg、5 mg、20 mg 规格,目录价 ¥1,695 起,仅供科研使用(RUO)。
03产品介绍
规格与货号
500101 | 1 mg | ¥1,695
500102 | 5 mg | ¥5,085
500103 | 20 mg | ¥12,204
Product Details
Product Description|Abciximab Biosimilar, Glycoprotein IIb/IIIa Receptor Monoclonal Antibody
Regulatory Status|RUO
Species specificity|Human
Min Sample Size|1 mg
Storage Conditions|4ºC
Maximal Shelf Life|12 months
See All Formats|Clone Abciximab
Background Information
Abciximab is a chimeric monoclonal antibody fragment developed to selectively bind and inhibit specific integrin receptors on platelet surfaces. Structurally, it is the Fab (antigen-binding) fragment of the monoclonal antibody 7E3, designed using recombinant DNA technology. This antibody originates from a murine (mouse) immunoglobulin engineered to contain both murine variable regions and human constant regions, resulting in a chimeric composition that combines high specificity with structural compatibility to human proteins. The molecule has a molecular mass of approximately 47.6 kilodaltons (kDa) and maintains the typical immunoglobulin Fab architecture, comprising one complete light chain and the variable and first constant domains of the heavy chain, connected via disulfide bonds.
Functionally, Abciximab exerts its activity through high-affinity binding to the glycoprotein (GP) IIb/IIIa receptor complex, also known as integrin αIIbβ3, on platelets. This receptor plays a crucial role in mediating platelet aggregation by serving as the final common pathway for fibrinogen, von Willebrand factor, and other adhesive ligand binding. By occupying the ligand-binding sites of this integrin complex, Abciximab sterically hinders the interaction between platelets and adhesive molecules, effectively inhibiting crosslinking and aggregation processes. In addition to the αIIbβ3 receptor, Abciximab also displays binding affinity toward related integrins such as αvβ3 and Mac-1 (CD11b/CD18), contributing to its ability to modulate a wider range of cell adhesion phenomena in research contexts.
At the molecular level, Abciximab's binding is non-competitive and characterized by slow dissociation kinetics, allowing the molecule to remain attached to its receptor targets for extended periods. The interaction occurs mainly through complementarity-determining regions (CDRs) located in the antibody’s variable domains, which recognize specific conformational epitopes on the integrin surface. Through these mechanisms, Abciximab provides a precise biochemical model for investigating integrin-mediated signaling, receptor-ligand dynamics, and the molecular regulation of platelet adhesion and aggregation.
Data Sheets
Cat # Size Price Quantity 5001011 mg Add to Cart5001025 mg Add to Cart50010320 mg Add to Cart
04完整参数表
参数由厂商资料整理,采购前请以最终报价单与技术协议为准。
05荣誉与资质
该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。
- 营业执照未上传
- 品牌授权未上传
- 产品检测报告未上传
- 会员身份
- 收费会员
- 经营身份
- 原厂
- 成立年份
- 2020 年
- 所在地
- 上海
- 收录条目
- 1865 个
- 平台核验
- 平台代管
06品牌与供应商
InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。
品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。
07同类条目
同一子类内的条目才具备可比性。跨子类比较参数通常没有意义。
08同品牌其他条目
上海英诺赛图 在本目录共 1865 个条目,除本条外还有:
科研在线(TeleVM). Anti-Human GP IIb/IIIa (Abciximab Biosimilar)(500101)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/anti-human-gp-iib-iiia-abciximab-biosimilar.html.
TeleVM. (2026, November 12). Anti-Human GP IIb/IIIa (Abciximab Biosimilar)(500101). 产品目录. https://www.suprotek.cn/products/item/anti-human-gp-iib-iiia-abciximab-biosimilar.html
@misc{biocsp_item_anti_human_gp_iib_iiia_abciximab_biosimilar,
title = {Anti-Human GP IIb/IIIa (Abciximab Biosimilar)(500101)},
author = {{科研在线}},
year = {2026},
howpublished = {产品目录},
note = {更新于 2026-11-12,产品目录},
url = {https://www.suprotek.cn/products/item/anti-human-gp-iib-iiia-abciximab-biosimilar.html}
}
GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。
许可:CC BY-NC 4.0 · 转载注明来源